Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

Journal of the American Academy of Dermatology, Journal Year: 2024, Volume and Issue: 91(2), P. 300 - 311

Published: April 21, 2024

Background Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective To evaluate outcome measures (PROMs) and the safety in patients with moderate-to-severe AD over a follow-up period up to 5 years. Methods Data were extracted from prospective, multicenter BioDay registry (October 2017 - 2022) treated practice. Results In total 1223 patients, 1108 adults 115 pediatric included. After ≥1 year treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8-8.7, 3.5-4.2, 2.9-3.1 adults, respectively, whilst these PROMs 8.9-10.9, 4.4-6.4, 3.0-3.7 respectively. At follow-up, overall work impairment decreased 40.1% 13.3-16.3% adults. Furthermore, class I obesity itch-dominant generally had less favorable treatment response. Of all 66.8% reported adverse event, conjunctivitis being most common(33.7%). Limitations The percentage missing values selected was 26% 46% patients. Conclusion addition safety, has demonstrated sustained effectiveness across various PROMs, underscoring patients' perspectives.

Language: Английский

---

Advances in the Relationship between Respiratory Viruses and Asthma

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(17), P. 5501 - 5501

Published: Aug. 24, 2023

Several studies have reported that viral infection is closely associated with the onset, progression, and exacerbation of asthma. The purpose this review to summarize role infections in pathogenesis asthma onset exacerbations, as well discuss interrelated protective risk factors current treatment options. Furthermore, we present knowledge innate immunological pathways driving host defense, including changes epithelial barrier. In addition, highlight importance genetics epigenetics virus susceptibility. Moreover, involvement etiology from bronchiolitis childhood wheezing described. characterization mechanisms action respiratory viruses most frequently related are mentioned.

Language: Английский

---

Effectiveness of biologics for patients with severe asthma: study protocol for an umbrella review of systematic reviews and meta-analyses

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e096874 - e096874

Published: April 1, 2025

Introduction Many systematic reviews and meta-analyses (SRs/MAs) have evaluated the efficacy of biologic therapies for severe asthma. However, overall quality these SRs/MAs is unclear, which may influence selection biologics lead to misleading clinical decisions. This umbrella review aims objectively evaluate reassess Thus, this study will provide reliable evidence practice. Methods analysis A search be performed in PubMed, Embase, Cochrane Library, Web Science, Scopus conference abstracts up 1 March 2025. Literature screening data extraction conducted according predefined inclusion exclusion criteria. We reporting quality, methodological using Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) 2020 statement, PRISMA Network Meta-Analysis 2015 checklist, MeaSurement Tool Assess 2, Risk Bias 1.0 Grading Recommendations Assessment, Development Evaluation system. Additionally, re-analysis outcomes R software (V.4.3.3). Ethics dissemination Since use publicly available data, ethics approval not required. The results disseminated through publication a peer-reviewed journal. PROSPERO registration number CRD42024607393.

Language: Английский

---

Effects of Dupilumab in Children and Adolescents With Moderate‐Severe Asthma: A Systematic Review of Clinical Trials

Pediatric Pulmonology, Journal Year: 2025, Volume and Issue: 60(5)

Published: May 1, 2025

ABSTRACT Objective To evaluate the benefits and harms of Dupilumab in children adolescents with moderate to severe asthma. Methods We conducted a systematic search Medline, Embase, Cochrane Controlled Register Trials, Clinical Trials Registries up August 18, 2024. Whenever possible, we performed meta‐analyses studies. The certainty evidence for each outcome was assessed using GRADE methodology. Results Seven publications from two multicenter RCTs were included. These studies included 408 (6−11 years old) 134 (12−17 old). Both funded by pharmaceutical company that manufactures Dupilumab. suggests probably leads substantial reduction annual rate exacerbations (incidence ratio [IRR]: 0.46, 95% CI: 0.31−0.67; certainty), particularly Th2 phenotype. improves quality life clinically meaningful extent (RR: 1.18, 1.01−1.29; certainty). However, it does not lead improvement asthma control (mean difference: −0.43, −0.56 −0.30; studies; certainty; minimal‐important‐difference: 0.5). frequency serious adverse events may be similar between placebo (4.8% vs. 4.5%; RR: 1.05, 0.41–2.68; low Finally, at 52 weeks, an important increase Z ‐score pre‐BD FEV1/FVC 1.45, 1.22–1.63; high Conclusion In uncontrolled asthma, those inflammatory phenotype, use reduced exacerbations, increases both percentage good pulmonary function parameters, minimal events.

Language: Английский

---

An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma

Children, Journal Year: 2024, Volume and Issue: 11(7), P. 843 - 843

Published: July 11, 2024

Severe asthma (SA) is still a demanding challenge in clinical practice. Type 2 inflammation the most common phenotype children and adolescents with SA. As result, anti-inflammatory drugs, mainly corticosteroids (CSs), represent first choice to reduce type inflammation. However, SA patients may require high inhaled oral CS doses achieve maintain control. Some patients, despite highest dosages, can even display uncontrolled asthma. Therefore, biological era constituted breakthrough managing this condition. Dupilumab monoclonal antibody directed against IL-4 receptor α-subunit (IL-4Rα), antagonizing both IL-13, has been approved for pediatric severe This review presents discusses recent published studies on dupilumab There convincing evidence that safe effective option as it exacerbations, use, improve lung function, control, quality of life, also caregivers. thorough diagnostic pathway mandatory, concerning phenotyping. In fact, ideal eligible candidate child or adolescent allergic phenotype.

Language: Английский

---

Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease—A Systematic Review

Diagnostics, Journal Year: 2024, Volume and Issue: 14(21), P. 2390 - 2390

Published: Oct. 26, 2024

Background: Over the last few decades, efficacy of biological therapies for COPD has been evaluated by different randomized controlled trials (RCTs). Still, evaluation real-world data and patient-reported outcome measures (PROMs) have not performed in this field before. In current work, we present a systematic literature review PROMs treatments COPD. Methods: Three large databases (MEDLINE/PubMed, Scopus, ScienceDirect) were utilized review. Clinical studies (RCT, cohorts, case series/reports) assessing patients with treated any therapy included. Results: The resulted twelve eligible (nine three “real-world” series/reports). included was mainly limited to severity burden respiratory symptoms. Most associated improved compared baseline, although placebo. Dupilumab only biologic proven RCT both objective subjective measures. One prior study reported patients’ self-perceived drug effects, none perceived disease status. Only 25 assessed setting all combined. Real-world retrospective form reports or series. Conclusions: There are on experience While missing, biases such as placebo effect must be considered, requiring their incorporation outcomes from prospective trials.

Language: Английский

---

Progress in the development of kinase inhibitors for treating asthma and COPD

Advances in pharmacology, Journal Year: 2023, Volume and Issue: unknown, P. 145 - 178

Published: Jan. 1, 2023

Language: Английский

---

IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy

Eye & ENT Research, Journal Year: 2024, Volume and Issue: 1(1), P. 39 - 48

Published: Jan. 12, 2024

Abstract Type 2 dominant inflammation in nasal mucosa is the key underlying pathophysiological mechanism of allergic rhinitis (AR) and most presentations chronic rhinosinusitis with polyps (CRSwNP). Interleukin‐4 (IL‐4) IL‐13 share common receptor subunits signaling molecules, which lead to various pathological changes different cells, playing roles pathogenesis type inflammation. Numerous clinical trials have shown that biologics targeting molecules IL‐4/IL‐13 pathway, especially IL‐4 alpha, can treat CRSwNP AR high efficacy, are generally well tolerated. Several been approved for treatment difficult‐to‐control CRSwNP, while others also show promising results. Here, we review its role inflammation, current targeted therapies related a focus on CRSwNP.

Language: Английский

---

Biologic therapies for severe asthma with persistent type 2 inflammation

Australian Prescriber, Journal Year: 2024, Volume and Issue: 47(2), P. 36 - 42

Published: April 22, 2024

Asthma is a chronic inflammatory airways disease with reversible airflow obstruction, characterised in the majority by type 2 airway inflammation. Type inflammation results secretion of interleukin-4, -5 and -13 airways, recruitment cells (especially eosinophils mast cells), changes such as mucus hypersecretion increased reactivity. Approximately 5 to 10% people asthma, despite optimal therapy adherence treatment inhaled corticosteroids long-acting beta

Language: Английский

---

Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort

Allergy and Asthma Proceedings, Journal Year: 2023, Volume and Issue: 45(1), P. e14 - e22

Published: Dec. 28, 2023

Background: Dupilumab has been shown to be effective in clinical trials for moderate-to-severe uncontrolled asthma. However, the efficacy of dupilumab real world and prediction treatment response have not well studied patients with Objective: To investigate explore predictors super-responders a Chinese retrospective cohort. Methods: From January 2021 through December 2022, asthma who were treated 4 months included. Symptom control, type 2 inflammatory biomarkers, lung function collected at baseline follow-up assessment. Super-responders defined as exacerbation-free, off maintenance oral corticosteroids (mOCS), score five-item Asthma Control Questionnaire (ACQ-5) <0.5. The uni- multivariable logistic regressions used construct predictive models based on features. Results: A total 53 After treatment, median (interquartile range [IQR]) ACQ-5 decreased from 1.8 (1.6-2.4) 0.4 (0.2-0.8) (p < 0.001), (IQR) number exacerbations, 0.0 (0.0-1.0) (0.0-0.0) = 0.005). dose mOCS (prednisone equivalent) 15.0 mg/day (8.8-22.5 mg/day) 2.5 (0.0-10.0 0.008) nine receiving mOCS. All assessment parameters, including sputum eosinophil significantly improved, while blood count did decline (530 cells/mm³ [300-815 cells/mm³] versus 560 [220-938 cells/mm³], p 0.710). taking dupilumab, 25 (47.2%) achieved super-response. age onset 42 years (odds ratio [OR] 7.471 [95% confidence interval {CI}, 1.286-43.394) fractional exhaled nitric oxide (FeNO) 25-50 ppb (OR 35.038 CI, 3.104-395.553]) predicted super-responders, which showed C-index 0.822 (95% 0.697-0.947). Conclusion: improved symptom markers, Airway eosinophils, rather than can reliable indicator therapeutic efficacy. early-onset medium-high level FeNO contributed super-responders.

Language: Английский

---